| 4 | Screening guidelines and recommendations for patients at high risk of developing endocrine cancers. (Geurts JL, Strong EA, Wang TS, Evans DB, Clarke CN) J Surg Oncol 2020 May;121(6):975-983 6 Citations |
| 1 | The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. (Bean JR, Hosford SR, Symonds LK, Owens P, Dillon LM, Yang W, Shee K, Schwartz GN, Marotti JD, Muller KE, Rosenkranz KM, Barth RJ, Chen VS, Agarwal VR, Miller TW) Breast Cancer Res Treat 2015 Jan;149(1):69-79 13 Citations |
| 1 | A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers. (Halperin DM, Phan AT, Hoff AO, Aaron M, Yao JC, Hoff PM) BMC Cancer 2014 Aug 02;14:561 12 Citations |
| 2 | The importance of a multidisciplinary approach to endocrine tumors. (Wang TS, Evans DB) Surgery 2010 Dec;148(6):1311-2 2 Citations |
| 1 | Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer. (Hwang RF, Wang H, Lara A, Gomez H, Chang T, Sieffert N, Moon Y, Ram S, Zimmerman S, Lee JH, Pisters PW, Tamm EP, Fleming JB, Abbruzzese JL, Evans DB) Ann Surg Oncol 2008 May;15(5):1356-66 55 Citations |
| 1 | RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. (Kouvaraki MA, Shapiro SE, Perrier ND, Cote GJ, Gagel RF, Hoff AO, Sherman SI, Lee JE, Evans DB) Thyroid 2005 Jun;15(6):531-44 251 Citations |
